Deal Flow
Letter · prints on one page
Transaction tear sheetData as of Nov 7, 2026
M&A · Healthcare · Buyer's industry: Biological Products, (No Diagnostic Substances)

Lexeo Therapeutics, Inc. to acquire Mantle Therapeutics

Announced Sep 22, 2026 · Closed Sep 29, 2026 · Private target

Deal value—
Premium—To unaffected price
EV / Adj. EBITDA—
ConsiderationCash and stock

Transaction

Acquirer
Lexeo Therapeutics, Inc. (LXEO)
Target
Mantle Therapeutics
Buyer type
Strategic
Offer price per share
—
Enterprise value
—
Status
Closed Sep 29, 2026

Deal protections

Not disclosed for private-company acquisitions.

Advisors

To the acquirer
Not disclosed
To the target
Not disclosed

Classification

Sector
Healthcare
Buyer's industry
Biological Products, (No Diagnostic Substances)
Sources
  • 8-K (EX-99.1) · Sep 22, 2026

Prepared with Castle from public SEC EDGAR filings. Figures are extracted automatically; verify against the source documents. Not investment advice.